Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | President, R&D | February 24, 2025 | February 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date February 24, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 159,121 |
Ending reported balance
After 2025-02-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-24 · Sale · Disposed 7,356 · Balance 160,785 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024. Row 2 · 2025-02-24 · Sale · Disposed 1,664 · Balance 159,121 F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's RSUs granted on February 22, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024.
F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's RSUs granted on February 22, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2021 Filed Apr 7, 2021 18:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 25,000 | $16.00 | $400,000.00 |
DisclosureSEC source: 0001209191-21-025942 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionRestricted Stock Units · Derivative | 2,685 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009202 · doc4.xml · derivative · entry 4 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,371 Underlying: Common Stock · 2,685 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. F5 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 894 | $77.45 | $69,239.85 |
DisclosureSEC source: 0000899243-21-009202 · doc4.xml · nonDerivative · entry 2 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,645 F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units. F3 · price: The broker sold shares of the Issuer's common stock for certain employees following the vesting of previously granted Restricted Stock Units, including the common stock reported on this Form 4 by the reporting person, at an average price of $77.4495. Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 2,685 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-009202 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $78.30 | $0.00 |
DisclosureSEC source: 0000899243-21-009202 · doc4.xml · derivative · entry 3 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,000 shares Expires 2031-02-25 F4 · derivative.exercise_date: This option award was granted on February 26, 2021. 1/4 of the shares underlying the award shall vest on February 26, 2022, with the remainder of the shares vesting in equal monthly installments following February 26, 2022 through February 26, 2025. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:09 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 3,315 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013363 · doc4.xml · derivative · entry 4 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,345 Underlying: Common Stock · 3,315 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award shall vest on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:09 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 2,437 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013363 · doc4.xml · derivative · entry 3 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,211 Underlying: Common Stock · 2,437 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 1, 2017, with the remainder of the shares vesting in equal monthly installments following June 1, 2017 through June 1, 2020. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:09 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 704 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013363 · doc4.xml · derivative · entry 2 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596 Underlying: Common Stock · 704 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:09 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 6,456 | $16.00 | $103,296.00 |
DisclosureSEC source: 0001209191-21-013363 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:45 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionRestricted Stock Units · Derivative | 2,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020799 · doc4.xml · derivative · entry 3 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,056 Underlying: Common Stock · 2,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:45 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 826 | $37.61 | $31,065.86 |
DisclosureSEC source: 0001209191-20-020799 · doc4.xml · nonDerivative · entry 2 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,398 F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units. F3 · price: The broker sold shares of Arvinas Common Stock for certain Arvinas employees following the vesting of previously granted Restricted Stock Units, including the Common Stock reported on this Form 4 by the Reporting Person, at an average price of $37.61. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:45 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 2,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020799 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:27 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $47.38 | $0.00 |
DisclosureSEC source: 0001209191-20-014636 · doc4.xml · derivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-02-26 F1 · derivative.exercise_date: This option award was granted on February 27, 2020. 1/4 of the shares underlying the award shall vest on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 18:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 11,742 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005638 · doc4.xml · derivative · entry 3 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,648 Underlying: Common Stock · 11,742 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option award was granted on September 26, 2018, 1/4 of the shares underlying the award vested as of June 1, 2017, with the remainder of the shares vesting in equal monthly installments following June 1, 2017 through June 1, 2020. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 18:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 1,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005638 · doc4.xml · derivative · entry 2 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award was granted on September 26, 2018, 1/4 of the shares underlying the award vested as of January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 18:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 13,042 | $16.00 | $208,672.00 |
DisclosureSEC source: 0001209191-20-005638 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 17:13 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 10,000 | $28.00 | $280,000.00 |
DisclosureSEC source: 0001209191-19-056788 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 17:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 1,000 | $24.05 | $24,050.00 |
DisclosureSEC source: 0001209191-19-055696 · doc4.xml · nonDerivative · entry 2 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.04 to $24.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 17:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 9,000 | $23.55 | $211,950.00 |
DisclosureSEC source: 0001209191-19-055696 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.03 to $24.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:53 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 1,300 | $22.54 | $29,302.00 |
DisclosureSEC source: 0001209191-19-051780 · doc4.xml · nonDerivative · entry 2 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.39 to $22.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:53 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 8,700 | $21.76 | $189,312.00 |
DisclosureSEC source: 0001209191-19-051780 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,796 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.36 to $22.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 16:30 UTC | ARVINAS, INC. ARVN · Entity 5355 | PurchaseCommon Stock | 1,000 | $14.66 | $14,660.30 |
DisclosureSEC source: 0000899243-19-009575 · doc4.xml · nonDerivative · entry 1 Taylor Ian · CIK 0001753281 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,496 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:29 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 65,427 | $0.00 Strike: $19.36 | $0.00 |
DisclosureSEC source: 0000899243-19-006234 · doc4.xml · derivative · entry 2 Taylor Ian · CIK 0001753281 · Senior Vice President, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,427 Underlying: Common Stock · 65,427 shares Expires 2029-02-28 F3 · derivative.exercise_date: This option award was granted on March 1, 2019. 1/4 of the shares underlying the award shall vest on March 1, 2020, with the remainder of the shares vesting in equal monthly installments following March 1, 2020 through March 1, 2023. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:29 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantRestricted Stock Units · Derivative | 10,742 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006234 · doc4.xml · derivative · entry 1 Taylor Ian · CIK 0001753281 · Senior Vice President, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,742 Underlying: Common Stock · 10,742 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 1, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 1, 2020. Read SEC document |
| September 26, 2018 Filed Sep 28, 2018 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 44,390 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025562 · doc4.xml · derivative · entry 4 Taylor Ian · CIK 0001753281 · Senior Vice President, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,390 Underlying: Common Stock · 44,390 shares Expires 2028-09-25 F4 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award shall vest on June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022. Read SEC document |
| September 26, 2018 Filed Sep 28, 2018 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 30,660 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025562 · doc4.xml · derivative · entry 3 Taylor Ian · CIK 0001753281 · Senior Vice President, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,660 Underlying: Common Stock · 30,660 shares Expires 2028-09-25 F3 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award shall vest on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022. Read SEC document |
| September 26, 2018 Filed Sep 28, 2018 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 2,600 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025562 · doc4.xml · derivative · entry 2 Taylor Ian · CIK 0001753281 · Senior Vice President, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires 2028-09-25 F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award shall vest on January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022. Read SEC document |
| September 26, 2018 Filed Sep 28, 2018 21:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 23,390 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025562 · doc4.xml · derivative · entry 1 Taylor Ian · CIK 0001753281 · Senior Vice President, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,390 Underlying: Common Stock · 23,390 shares Expires 2028-09-25 F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 1, 2017, with the remainder of the shares vesting in equal monthly installments following June 1, 2017 through June 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.